logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10300127 B1

PDFFull Text
Date of Patent:
May. 28, 2019

Filed:

Mar. 21, 2016

Immune complex

Applicant:

The Rockefeller University, New York, NY (US);

Inventors:

Jeffrey V. Ravetch, New York, NY (US);

Taia Wang, New York, NY (US);

Jad Mamaary, New York, NY (US);

Assignee:

The Rockefeller University, New York, NY (US);

Attorney:

Fox Rothschild LLP

Primary Examiner:

Nianxiang Zou

Int. Cl.
CPC ...
A61K 39/42 (2006.01); A61K 39/12 (2006.01); A61K 39/145 (2006.01); C07K 16/10 (2006.01); A61P 31/16 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); C07K 14/005 (2006.01); C07K 14/47 (2006.01);
U.S. Cl.
CPC ...
A61K 39/145 (2013.01); A61K 39/0011 (2013.01); A61K 39/12 (2013.01); A61K 39/42 (2013.01); A61K 45/06 (2013.01); A61P 31/16 (2018.01); A61P 35/00 (2018.01); C07K 14/005 (2013.01); C07K 14/4748 (2013.01); C07K 16/1018 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/55516 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/41 (2013.01); C07K 2317/72 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C12N 2760/16134 (2013.01);
Abstract

The present invention relates to immunogenic immune complexes, related compositions, and related methods. This invention addresses the above-described un-met need by providing an immune complex (IC) or immune complexes (ICs), which take advantages of Type II Fc receptor (FcR) interactions and signaling to elicit broader and more potent protective immune responses. In one aspect, the invention provides an immune complex comprising an antigenic agent and an isolated protein. The protein comprises an IgG Fc region and is capable of binding to a Type II Fc receptor. Preferably, the protein is an antibody or an Fc region-containing fragment thereof.

Find Patent Forward Citations

Loading…